In male ZDF rats, Dapagliflozin at doses of 1.0 mg/kg/day can suppress hyperglycemia, thus changing the serum CT level then alleviating the calcium loss via the kidney, hence preventing diabetic bone resorption. Here, CALCA is linked to Hyperglycemia.